DeckTherapeutics appoints Professor Yechezkel Barenholz, PhD to its Board of Directors
DeckTherapeutics today announced that it has appointed Dr. Yechezkel (Chezy) Barenholz to its Board of Directors.
Professor Barenholz is a professor emeritus of biochemistry and cancer research at the Hebrew University‐Hadassah Medical School, Jerusalem, and a recognized expert in the field of drug delivery. He is the author of over 430 publications many of which are widely cited.
Professor Barenholz is a co-inventor of over 55 patent families including being one of the major inventors of Doxil® (pegylated nano-liposomes remote loaded with the anticancer drug doxorubicin for cancer treatment. Doxil® is the first nano-drug approved by FDA as well as being the first liposomal drug approved by the FDA. Doxil® was marketed in the US by Johnson & Johnson and in Europe by Schering Plough (as Caelyx). Now it is marketed by Baxter. Over 1,000,000 cancer patients are treated so-far globally with Doxil or its four generic versions.
Prof. Barenholz is founder of several prominent startup companies, including; Ayana Pharma Ltd that under his guidance achieved FDA approval of one of the 4 versions of FDA approved generic Doxil, now sold in the USA as well as the clinical stage Moebius Medical Ltd.
DeckTherapeutics is pioneering acute IV injection of omega-3 diglycerides as safe and uniquely effective first-in-class therapeutics for the prevention of acute hypoxic-ischemic injuries. Our proprietary diglyceride technology platform enables greatly enhanced delivery and cytoprotective effects of omega-3 fatty acids and their specialized pro-resolving mediator derivatives. Lead compound THDG3 is strongly neuroprotective in various in vivo models of acute hypoxic-ischemic injury and holds potential to address some of the largest unmet medical needs. THDG3 will first be developed in the rare pediatric disease hypoxic-ischemic encephalopathy (HIE), brain damage in newborns deprived of oxygen during birth. HIE is a main cause of cerebral palsy, epilepsy, low IQ and mortality in infants. DeckTherapeutics is led by an experienced leadership team and is supported by a world-class Scientific Advisory Board. For more information, please visit www.decktherapeutics.com.